Daan Gene Co., Ltd. (SHE:002030)

Market Cap	7.65B -21.4%
Revenue (ttm)	737.96M -10.4%
Net Income	-895.46M
EPS	-0.63
Shares Out	1.40B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,318,228
Open	5.34
Previous Close	5.34
Day's Range	5.33 - 5.45
52-Week Range	4.80 - 8.20
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Daan Gene

Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers PCR testing kits, including hepatitis virus, human papillomavirus (HPV), sexually transmitted infections sexually transmitted infections, human immunodeficiency virus, blood screening, respiratory infections, digestive pathogens, public health, coronavirus...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 1,506
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002030

Financial Performance

In 2025, Daan Gene's revenue was 757.66 million, a decrease of -11.18% compared to the previous year's 853.02 million. Losses were -744.38 million, -19.54% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 31, 2026

Data Sources Report a data error